Charles River Laboratories (CRL) was Initiated by Gabelli & Co to “Buy” and the brokerage firm has set the Price Target at $96. Gabelli & Co advised their investors in a research report released on Apr 26, 2016.
On the company’s financial health, Charles River Laboratories reported $1.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 10, 2016. Analyst had a consensus of $0.94. The company had revenue of $353.90 million for the quarter, compared to analysts expectations of $349.22 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS.
Charles River Laboratories opened for trading at $80.88 and hit $81.335 on the upside on Friday, eventually ending the session at $80.99, with a gain of 0.21% or 0.17 points. The heightened volatility saw the trading volume jump to 2,08,425 shares. Company has a market cap of $3,784 M.
In a different news, on Apr 8, 2016, Davide Molho (Corporate Executive VP) sold 30,667 shares at $80.00 per share price. According to the SEC, on Mar 4, 2016, James C Foster (Chairman, President and CEO) sold 20,072 shares at $75.00 per share price. On Mar 4, 2016, Nancy Gillett (Corporate Executive VP) sold 822 shares at $75.82 per share price, according to the Form-4 filing with the securities and exchange commission.
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.